TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01219153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended high dose letrozole regimen /GnRH antagonist protocol
Description: Letrozole (Femara; Novertis pharma AG, Basle, Switzerland) is administered starting on cycle day one for 8 consecutive days . The dose of letrozole is 5mg /day during the first 5 days of cycle and 2.5 mg/day during the subsequent 3 days .~Highly purified urinary FSH (HP-uFSH) (Fostimon, IBSA) 300 IU/day is started on cycle day 5 and is continued until and including the day of HCG administration. Starting from cycle day 8 , the dose of HP-uFSH is adjusted individually according to ovarian response which is monitored using transvaginal ultrasound and serum estradiol.~GnRH antagonist (cetrorelix acetate)(Cetrotide®) 0.25 mg S.C once daily is started when the leading follicle is 14 mm in mean diameter and is continued until and including the day of HCG administration .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Short low dose letrozole regimen /GnRH antagonist protocol
Description: Letrozole (Femara; Novertis pharma AG, Basle, Switzerland)2.5 mg /daily is administered for 5 consecutive days starting on cycle day 3.~Highly purified urinary FSH (HP-uFSH) (Fostimon, IBSA) 300 IU/day is started on cycle day 3 and is continued until and including the day of HCG administration. Starting from cycle day 8 , the dose of HP-uFSH is adjusted individually according to ovarian response which is monitored using transvaginal ultrasound and serum estradiol.~GnRH antagonist (cetrorelix acetate)(Cetrotide®) 0.25 mg S.C once daily is started when the leading follicle is 14 mm in mean diameter and is continued until and including the day of HCG administration .
Study: NCT02693041

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: probiotic
Description: Low-risk women, women with prior preeclampsia and women with a prior preterm birth will be randomized to be treated with LGG during pregnancy. Effect on maternal and perinatal outcome as well as the effect of treatment on immunological and inflammatory biomarkers will be evaluated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: probiotic
Description: Low-risk women, women with prior preeclampsia and women with a prior preterm birth will be randomized to be treated with LGG during pregnancy. Effect on maternal and perinatal outcome as well as the effect of treatment on immunological and inflammatory biomarkers will be evaluated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Low-risk women, women with prior preeclampsia and women with a prior preterm birth will be randomized to be treated with placebo during pregnancy. Effect on maternal and perinatal outcome as well as the effect of treatment on immunological and inflammatory biomarkers will be evaluated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Low-risk women, women with prior preeclampsia and women with a prior preterm birth will be randomized to be treated with placebo during pregnancy. Effect on maternal and perinatal outcome as well as the effect of treatment on immunological and inflammatory biomarkers will be evaluated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Low-risk women, women with prior preeclampsia and women with a prior preterm birth will be randomized to be treated with placebo during pregnancy. Effect on maternal and perinatal outcome as well as the effect of treatment on immunological and inflammatory biomarkers will be evaluated.
Study: NCT00889512

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Luveris fixed dose
Description: Luveris 75IU daily throughout ovarian stimulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luveris increasing dose
Description: Luveris 75IU until estradiol level reaches 250 pg/ml then increasing to 75IU BID for two days, then TID until hCG
Study: NCT01051336

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TARIS Placebo

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Study: NCT01937260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brodalumab
Description: Group 1 consists of 20 subjects and will receive 2 oral doses of midazolam and a single SC dose of brodalumab. Group 2 consists of 10 subjects and will receive a single SC dose of brodalumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brodalumab
Description: Group 1 consists of 20 subjects and will receive 2 oral doses of midazolam and a single SC dose of brodalumab. Group 2 consists of 10 subjects and will receive a single SC dose of brodalumab.
Study: NCT00801229

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vyvanse
Description: Vyvanse 30, 50, or 70 mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 30, 50, 70 mg daily
Study: NCT02930902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paricalcitol
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgical resection of tumor

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgical resection of tumor
Study: NCT04044339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-5202
Description: Study Drug to be administered orally
Study: NCT02997033

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT01448018

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: 3 monthly intravitreous injection as soon as possible after the inclusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: 3 monthly intravitreous injection as soon as possible after the inclusion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hemodilution
Description: hemodilution using erythrocytapheresis - target hematocrit: 35% - as soon as possible after the inclusion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hemodilution
Description: hemodilution using erythrocytapheresis - target hematocrit: 35% - as soon as possible after the inclusion
Study: NCT04061603

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adagio AF Cryoablation System (iCLAS™)
Description: Endovascular ablation of the left and right atrium
Study: NCT02153944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propranolol 40 mg was given orally during study visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Methylphenidate 20mg was given orally during study visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Methylphenidate 20mg was given orally during study visit

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was given orally during study visit

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was given orally during study visit
Study: NCT04671459

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TTFields and SRS
Description: SRS procedure will be delivered within 7 days after start of TTFields therapy . A 5-day SRS regimen is allowed. TTFields should be interrupted in time of SRS and start immediately after.
Study: NCT00994331

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention
Description: non surgical procedure to open blocked coronary arteries

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention
Description: non surgical procedure to open blocked coronary arteries

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention
Description: non surgical procedure to open blocked coronary arteries
Study: NCT03790826

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cystoscopy
Description: Comparison of bladder mucosa via cystoscopy.
Study: NCT02777125

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Metered Dose Inhaler
Description: A metered dose inhaler (MDI) is a small hand held pressurized canister device that contains both a medication, in this case albuterol, and a propellant. Pressing the device delivers 90mcg of albuterol. The MDI is attached to a spacer device, which is a one way holding chamber which allows the medication to be delivered over a series of breaths.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Breath Actuated Nebulizer
Description: The breath actuated nebulizer (BAN) device is a device that converts liquid medication, in this case albuterol, into an aerosol. It consists of a mouthpiece, a medication reservoir, and connective tubing that attaches to a compressor. This BAN device delivers medication when the patient takes a breath, but it can be attached to a mask and set to continuous nebulization for patients that are not able to coordinate their breaths.
Study: NCT01533246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linsitinib
Description: Oral Linsitinib 150mg, twice a day, days 1- 28

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04044339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-5202
Description: Study Drug to be administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to be administered orally
Study: NCT03157804

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Genetically Engineered Hematopoietic Stem/Progenitor Cells
Description: Undergo infusion of genetically modified hematopoietic progenitor cell therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given subcutaneously (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Given SC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Study: NCT02567513

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supplement Intervention
Description: Supplements given twice/day, 5 days/week, for 24 weeks by research staff.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Snack Intervention
Description: Snacks given twice/day, 5 days/week for 24 weeks by research staff.
Study: NCT02018289

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Triclosan coated suture
Description: Suture of the abdominal wall with triclosan coated suture
Study: NCT04044339

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to be administered orally
Study: NCT01905878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS1033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS1033
Study: NCT00654082

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sildenafil
Description: sildenafil 50 mg tablet by mouth 1 hour prior to anticipated sexual activity, but not more than once daily (QD) for 6 weeks; after 2 weeks on treatment, doses could be escalated to 100 mg or reduced to 25 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablet by mouth 1 hour prior to anticipated sexual activity, but not more than once daily (QD) for 6 weeks
Study: NCT00370916

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician-initiated medication reconciliation
Description: Physician house staff performed and documented medication reconciliation after hospital admission with the assistance of a CPRS template

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist-initiated medication reconciliation
Description: Pharmacist performed and documented medication reconciliation
Study: NCT03223337

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daprodustat (GSK1278863)
Description: Daprodustat (GSK1278863) 6 mg tablet will be given to all subjects as a single dose via oral route. Daprodustat (GSK1278863) is a 9.0 millimeter (mm) round, compound radius, white film coated tablet.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daprodustat (GSK1278863)
Description: Daprodustat (GSK1278863) 6 mg tablet will be given to all subjects as a single dose via oral route. Daprodustat (GSK1278863) is a 9.0 millimeter (mm) round, compound radius, white film coated tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daprodustat (GSK1278863)
Description: Daprodustat (GSK1278863) 6 mg tablet will be given to all subjects as a single dose via oral route. Daprodustat (GSK1278863) is a 9.0 millimeter (mm) round, compound radius, white film coated tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daprodustat (GSK1278863)
Description: Daprodustat (GSK1278863) 6 mg tablet will be given to all subjects as a single dose via oral route. Daprodustat (GSK1278863) is a 9.0 millimeter (mm) round, compound radius, white film coated tablet.
Study: NCT01183949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT7519M
Description: Part A: Nine patients will receive AT7519M as an intravenous infusion on days 1, 4, 8 and 11 of a three week cycle. The starting dose of AT7519M will be 21mg/m\^2/dose and will be increased to 27mg/m\^2/dose during subsequent cycles in the absence of AT7519M-related toxicities.~Part B: Amendment clarified there will be no further exploration of AT7519M as a monotherapy.~Part C: Amendment modified dose escalation to a conventional 3 + 3 design with a maximum total of 14 patients will be treated at the maximum tolerated dose.
Study: NCT02018289

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: No triclosan
Description: Suture of the abdominal wall with suture without triclosan coat
Study: NCT00654069

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets every 6 hours for 48 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acurox 5/30 mg
Description: 2 tablets every 6 hours for 48 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acurox 7.5/30
Description: 2 tablets every 6 hours for 48 hours
Study: NCT00003724

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical procedure
Study: NCT03764722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan
Description: The patient will initially receive a standard dose of 0.1 mcg/kgmc/min. In case of good tolerance of the drug - the dose will be increased to 0.2 mcg/kgmc/min. If hypotension SBP \<90 mmHg occurs, the dose will be reduced to 0.05 mcg / kgm / min. If the hypotension persists despite the reduction of the drug - the infusion will be terminated and the patient will be excluded from the study. The infusion will be terminated within 24 hours, the patient will be examined again 4 hours after the end of the infusion, by the attending physician and unless there are contraindications - discharged home.~Patients will be hospitalized every 4 weeks for the next 6 months.
Study: NCT02271308

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-resistance elastic band training
Description: The residents in experimental group will receive a low-resistance elastic band training (30 minutes), including warm-up and cold-down period, three times per week for 12 weeks.
Study: NCT02781103

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guided imagery plus active tDCS
Description: The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device and audio headphones will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. The subject will listen to a scripted guided imagery CD specifically developed for women with chronic pelvic pain through the audio headphones. The guided imagery plus active tDCS arm will have tDCS for 20 minutes concurrently with Guided Imagery.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Guided imagery plus Sham tDCS
Description: The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device and audio headphones will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. The subject will listen to a scripted guided imagery CD specifically developed for women with chronic pelvic pain through the audio headphones. The sham arm will have 30 seconds of tDCS, but after 30 seconds the device will be turned off. The device will remain in place until the subject has listened to 20 minutes of the guided imagery CD.
Study: NCT00889343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 2x200 mg filmcoated tablets BID on day 2-12 of a 14-days cycle, oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 filmcoated tablets BID, day 2-12 of a 14-days cycle, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin or Irinotecan
Description: Oxaliplatin 100 mg/m2 intravenous infusion on day 1 of 14-days cycle, Irinotecan 180 mg/m2 intravenous infusion on day 1 of 14-days cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxaliplatin or Irinotecan
Description: Oxaliplatin 100 mg/m2 intravenous infusion on day 1 of 14-days cycle, Irinotecan 180 mg/m2 intravenous infusion on day 1 of 14-days cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 400 mg/m2 intravenous infusion on day 1 of a 14-days cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Leucovorin
Description: 400 mg/m2 intravenous infusion on day 1 of a 14-days cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 400 mg/m2 intravenous bolus infusion on day 1, 2400 mg/m2 46 hour intravenous infusion on day 1 to 2 of a 14-days cycle
Study: NCT01183949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Part C will treat between 3-26 patients with a combination of bortezomib and AT7519M in a dose escalation design. The starting doses for the dose escalation are bortezomib 1 mg/m2 and AT7519M 14 mg/m2.
Study: NCT02813291

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: All subjects will mentally repeat a complex finger sequence with the left hand, for 13 min:~- Subjects of the Stimulation groups (Young Stim and Elderly Stim) will receive in parallel an anodal tDCS of the primary motor cortex.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: All subjects will mentally repeat a complex finger sequence with the left hand, for 13 min:~- Subjects of the Stimulation groups (Young Stim and Elderly Stim) will receive in parallel an anodal tDCS of the primary motor cortex.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: All subjects will mentally repeat a complex finger sequence with the left hand, for 13 min:~- Subjects of the Sham groups (Young Sham and Elderly Sham) will receive in parallel a sham tDCS of the primary motor cortex.
Study: NCT00889343

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-Fluorouracil
Description: 400 mg/m2 intravenous bolus infusion on day 1, 2400 mg/m2 46 hour intravenous infusion on day 1 to 2 of a 14-days cycle
Study: NCT01883401

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Freeze-dried strawberries
Description: 25g or 50g freeze-dried strawberries reconstituted in water

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Freeze-dried strawberries
Description: 25g or 50g freeze-dried strawberries reconstituted in water

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Dietary fiber
Description: 4g or 8g dietary fiber blended in water

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Dietary fiber
Description: 4g or 8g dietary fiber blended in water
Study: NCT01400867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil
Description: Subjects ≥ 6 months old: 12 mg/kg IV for subjects weighing ≤ 33 kg and 400 mg for subjects weighing \> 33 kg will be infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour)~Subjects \< 6 months old: 8mg/kg infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam
Description: Vancomycin 15mg/kg IV over 60 minutes (or a maximum of 10mg/min whichever is longer) +/- Aztreonam 30 mg/kg IV every 8 hours over 60 minutes (for infections involving gram negative pathogen suspected or confirmed)~Cefazolin 75mg/kg IV divided every 8 hours over 60 minutes (for sites that do not empirically cover for MRSA) +/- Aztreonam 30 mg/kg IV every 8 hours over 60 minutes (for infections involving gram negative pathogen suspected or confirmed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin or Clindamycin or Linezolid
Description: Possible oral switch on or after study day 4.~Cephalexin: 25 mg/kg q6h PO or Clindamycin: 10 mg/kg q8h PO or Linezolid 600mg q12h (cohort 1) or 10 mg/kg q8h (cohorts 2,3 and 4) PO.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cephalexin or Clindamycin or Linezolid
Description: Possible oral switch on or after study day 4.~Cephalexin: 25 mg/kg q6h PO or Clindamycin: 10 mg/kg q8h PO or Linezolid 600mg q12h (cohort 1) or 10 mg/kg q8h (cohorts 2,3 and 4) PO.
Study: NCT03060434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline Oral Tablet
Description: patient will receive for 15 days: Ibuprofen 600 mg bid; pregabalin 75 mg bid; paracetamol 1 g tid; pentoxifylline 400 mg bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: patient will receive for 15 days: Ibuprofen 600 mg bid; pregabalin 75 mg bid; paracetamol 1 g tid